Mantle Cell Lymphoma

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	pirtobrutinib Sensitive: A1 - Approval Eli Lilly Press Release - 4 days (New A1) pirtobrutinib Sensitive : A1 Eli Lilly Press Release - 4d	pirtobrutinib Sensitive: A1 - Approval Eli Lilly Press Release - 4 days pirtobrutinib Sensitive : A1 Eli Lilly Press Release - 4 days - (New A1)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	temsirolimus Sensitive: A1 - Approval temsirolimus Sensitive : A1	temsirolimus Sensitive: A1 - Approval temsirolimus Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	rituximab + bortezomib Sensitive: A1 - Approval rituximab + bortezomib Sensitive : A1	rituximab + bortezomib Sensitive: A1 - Approval rituximab + bortezomib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	bortezomib Sensitive: A1 - Approval bortezomib Sensitive : A1	bortezomib Sensitive: A1 - Approval bortezomib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	ibrutinib + rituximab + lenalidomide Sensitive: A2 - Guideline ibrutinib + rituximab + lenalidomide Sensitive : A2	ibrutinib + rituximab + lenalidomide Sensitive: A2 - Guideline ibrutinib + rituximab + lenalidomide Sensitive : A2
ALK negative	Mantle Cell Lymphoma	ALK negative	Mantle Cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	VR-CAP Sensitive: A2 - Guideline VR-CAP Sensitive : A2	VR-CAP Sensitive: A2 - Guideline VR-CAP Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	R-DHAP Sensitive: A2 - Guideline R-DHAP Sensitive : A2	R-DHAP Sensitive: A2 - Guideline R-DHAP Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	R-DHAX Sensitive: A2 - Guideline R-DHAX Sensitive : A2	R-DHAX Sensitive: A2 - Guideline R-DHAX Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	R-CVAD Sensitive: A2 - Guideline R-CVAD Sensitive : A2	R-CVAD Sensitive: A2 - Guideline R-CVAD Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	R-GemOx Sensitive: A2 - Guideline R-GemOx Sensitive : A2	R-GemOx Sensitive: A2 - Guideline R-GemOx Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	venetoclax + rituximab Sensitive: A2 - Guideline venetoclax + rituximab Sensitive : A2	venetoclax + rituximab Sensitive: A2 - Guideline venetoclax + rituximab Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	R-CHOP Sensitive: A2 - Guideline R-CHOP Sensitive : A2	R-CHOP Sensitive: A2 - Guideline R-CHOP Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	ibrutinib + rituximab Sensitive: A2 - Guideline ibrutinib + rituximab Sensitive : A2	ibrutinib + rituximab Sensitive: A2 - Guideline ibrutinib + rituximab Sensitive : A2
CCR7 positive	Mantle Cell Lymphoma	CCR7 positive	Mantle Cell Lymphoma	brexucabtagene autoleucel Sensitive: B - Late Trials brexucabtagene autoleucel Sensitive : B	brexucabtagene autoleucel Sensitive: B - Late Trials brexucabtagene autoleucel Sensitive : B
ABCB1 mutation + VEGFA mutation	Mantle Cell Lymphoma	ABCB1 mutation + VEGFA mutation	Mantle Cell Lymphoma	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B
VEGFA mutation	Mantle Cell Lymphoma	VEGFA mutation	Mantle Cell Lymphoma	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B
ABCB1 mutation	Mantle Cell Lymphoma	ABCB1 mutation	Mantle Cell Lymphoma	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	INCB50465 Sensitive: B - Late Trials INCB50465 Sensitive : B	INCB50465 Sensitive: B - Late Trials INCB50465 Sensitive : B
CCND1 overexpression	Mantle Cell Lymphoma	CCND1 overexpression	Mantle Cell Lymphoma	INCB50465 Sensitive: C2 – Inclusion Criteria INCB50465 Sensitive : C2	INCB50465 Sensitive: C2 – Inclusion Criteria INCB50465 Sensitive : C2
TP53 mutation	Mantle Cell Lymphoma	TP53 mutation	Mantle Cell Lymphoma	ibrutinib + rituximab Sensitive: C2 – Inclusion Criteria ibrutinib + rituximab Sensitive : C2	ibrutinib + rituximab Sensitive: C2 – Inclusion Criteria ibrutinib + rituximab Sensitive : C2

Mantle Cell Lymphoma

Associations(105)

Associations
(105)